HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SIP(F8)-SS-DM1

an antineoplastic agent that targets solid tumors

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Casi, Giulio: 2 articles (11/2015 - 05/2014)
2.	Neri, Dario: 2 articles (11/2015 - 05/2014)
3.	Gébleux, Rémy: 1 article (11/2015)
4.	Wulhfard, Sarah: 1 article (11/2015)
5.	Bernardes, Gonçalo J L: 1 article (05/2014)
6.	Krall, Nikolaus: 1 article (05/2014)
7.	Perrino, Elena: 1 article (05/2014)
8.	Pretto, Francesca: 1 article (05/2014)
9.	Steiner, Martina: 1 article (05/2014)

Related Diseases

1.

Neoplasms (Cancer)

05/01/2014 - "Quantitative biodistribution studies and microscopic analyses confirmed a preferential accumulation of SIP(F8)-SS-DM1 in the subendothelial extracellular matrix of tumors, similar to the pattern observed for unmodified antibody. "
05/01/2014 - "The DM1 conjugate SIP(F8)-SS-DM1 mediated potent antitumor activity in mice bearing DM1-sensitive F9 tumors but not DM1-insensitive CT26 tumors. "
11/01/2015 - "Therapy experiments in immunocompetent mice bearing murine F9 tumors revealed that SIP(F8)-SS-DM1 was more efficacious than IgG(F8)-SS-DM1 when the two products were compared either in an equimolar basis or at equal milligram doses."
11/01/2015 - "In both cases, DM1 was coupled to unpaired cysteine residues, resulting in a drug-antibody ratio of 2. In biodistribution studies, SIP(F8)-SS-DM1 accumulated in the tumor and cleared from circulation more rapidly than IgG(F8)-SS-DM1. "

Related Drugs and Biologics

1.	Cysteine (L-Cysteine)

Related Therapies and Procedures

1.	Therapeutics